WAT
47
5
ED
48
3
IP
70
2
CAG
30
4
DVN
16
3
AFL
46
-3
PBI
60
-5
MS
74
-2
CVX
46
5
HIG
67
4
PDCO
35
-3
URI
53
-2
PVH
52
-3
EXPE
88
2
DHI
48
3
SYF
85
2
JWN
40
-2
DE
46
3
VTR
49
-3
HAS
30
2
WAT
47
5
ED
48
3
IP
70
2
CAG
30
4
DVN
16
3
AFL
46
-3
PBI
60
-5
MS
74
-2
CVX
46
5
HIG
67
4
PDCO
35
-3
URI
53
-2
PVH
52
-3
EXPE
88
2
DHI
48
3
SYF
85
2
JWN
40
-2
DE
46
3
VTR
49
-3
HAS
30
2
Financhill
Back

Royalty Pharma PLC Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
30

RPRX
Royalty Pharma PLC

Last Price:
26.38
Seasonality Move:
1.9%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Royalty Pharma PLC Price Quote

$26.38
+0.16 (+0.61%)
(Updated: November 21, 2024 at 5:55 PM ET)

Royalty Pharma PLC Key Stats

Sell
30
Royalty Pharma PLC (RPRX) is a Sell
Day range:
$26.23 - $26.67
52-week range:
$25.10 - $31.66
Dividend yield:
3.26%
P/E ratio:
10.20
P/S ratio:
6.79
P/B ratio:
1.67%
Volume:
2M
Avg. volume:
2.6M
1-year change:
-2.64%
Market cap:
$11.5B
Revenue:
$2.4B
EPS:
$2.55

How Much Does Royalty Pharma PLC Make?

Is Royalty Pharma PLC Growing As A Company?

  • What Is Royalty Pharma PLC's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.05%
  • What Is Royalty Pharma PLC's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 6.56%

Royalty Pharma PLC Stock Price Performance

What Is Royalty Pharma PLC 52-Week High & Low?

Royalty Pharma PLC Price To Free Cash Flow

Is It Risky To Buy Royalty Pharma PLC?

Is Royalty Pharma PLC Cash Flow Positive?

  • What Is RPRX Cash Flow From Operations?
    Cash flow from operations (TTM) is $2.8B
  • What Is Royalty Pharma PLC’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $387.2M
  • What Is Royalty Pharma PLC’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$3.2B

Royalty Pharma PLC Return On Invested Capital

  • Is Management Doing A Good Job?
    RPRX return on invested capital is 6.89%
  • What Is Royalty Pharma PLC Return On Assets?
    ROA measures how assets are converting to revenues and is 6.81%
  • What Is RPRX Return On Equity?
    ROE is a measure of profitability and is 11.56%

Royalty Pharma PLC Earnings Date & Stock Price

Royalty Pharma PLC Competitors

  • Who Are Royalty Pharma PLC's Competitors?
    Below is a list of companies who compete with Royalty Pharma PLC or are related in some way:
    • Arbutus Biopharma Corp (ABUS)
    • Amicus Therapeutics Inc (FOLD)
    • Geron Corp (GERN)
    • Ionis Pharmaceuticals Inc (IONS)
    • Syndax Pharmaceuticals Inc (SNDX)

Royalty Pharma PLC Dividend Yield

Royalty Pharma PLC Analyst Estimates

YoY Growth Past Surprise
EPS: 656.25% 12.07%
Revenue: 5.29% -22.8%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 41.43
Upside from Last Price: 58%

Major Shareholders

  • How many RPRX shares are owned by institutional investors?
    592.3M RPRX shares are owned by institutional investors
  • How many RPRX shares are owned by insiders?
    896.1K RPRX shares are owned by insiders